WallStreetZenWallStreetZen

NASDAQ: FREQ
Frequency Therapeutics Inc Stock

$0.36-0.02 (-5.26%)
Updated Sep 25, 2023
FREQ Price
$0.36
Fair Value Price
$1.52
Market Cap
$13.15M
52 Week Low
$0.33
52 Week High
$5.59
P/E
-0.19x
P/B
0.29x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$67.25M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.75
Operating Cash Flow
-$50M
Beta
1
Next Earnings
Nov 6, 2023
Ex-Dividend
N/A
Next Dividend
N/A

FREQ Overview

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how FREQ scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

FREQ ($0.36) is undervalued by 76.26% relative to our estimate of its Fair Value price of $1.52 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
FREQ ($0.36) is significantly undervalued by 76.26% relative to our estimate of its Fair Value price of $1.52 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
FREQ is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more FREQ due diligence checks available for Premium users.

Be the first to know about important FREQ news, forecast changes, insider trades & much more!

FREQ News

Valuation

FREQ fair value

Fair Value of FREQ stock based on Discounted Cash Flow (DCF)
Price
$0.36
Fair Value
$1.52
Undervalued by
76.26%
FREQ ($0.36) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
FREQ ($0.36) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
FREQ is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

FREQ price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.19x
Industry
12.93x
Market
14.28x

FREQ price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.29x
Industry
5.09x
FREQ is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

FREQ's financial health

Profit margin

Revenue
$0.0
Net Income
-$10.8M
Profit Margin
0%
FREQ's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$79.4M
Liabilities
$34.0M
Debt to equity
0.75
FREQ's short-term assets ($48.38M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FREQ's short-term assets ($48.38M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FREQ's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$8.4M
Investing
$19.2M
Financing
-$11.7M
FREQ's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

FREQ vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
FREQ$13.15M-5.51%-0.19x0.29x
IMPL$13.09M+0.18%-0.14x-0.17x
ACST$13.26M+0.56%-0.32x0.21x
ELOX$13.32M-3.59%-0.42x-0.72x
ZIVO$13.43M-8.21%-1.40x-4.27x

Frequency Therapeutics Stock FAQ

What is Frequency Therapeutics's quote symbol?

(NASDAQ: FREQ) Frequency Therapeutics trades on the NASDAQ under the ticker symbol FREQ. Frequency Therapeutics stock quotes can also be displayed as NASDAQ: FREQ.

If you're new to stock investing, here's how to buy Frequency Therapeutics stock.

What is the 52 week high and low for Frequency Therapeutics (NASDAQ: FREQ)?

(NASDAQ: FREQ) Frequency Therapeutics's 52-week high was $5.59, and its 52-week low was $0.33. It is currently -93.56% from its 52-week high and 9.09% from its 52-week low.

How much is Frequency Therapeutics stock worth today?

(NASDAQ: FREQ) Frequency Therapeutics currently has 36,520,750 outstanding shares. With Frequency Therapeutics stock trading at $0.36 per share, the total value of Frequency Therapeutics stock (market capitalization) is $13.15M.

Frequency Therapeutics stock was originally listed at a price of $13.70 in Oct 3, 2019. If you had invested in Frequency Therapeutics stock at $13.70, your return over the last 3 years would have been -97.37%, for an annualized return of -70.27% (not including any dividends or dividend reinvestments).

How much is Frequency Therapeutics's stock price per share?

(NASDAQ: FREQ) Frequency Therapeutics stock price per share is $0.36 today (as of Sep 25, 2023).

What is Frequency Therapeutics's Market Cap?

(NASDAQ: FREQ) Frequency Therapeutics's market cap is $13.15M, as of Sep 27, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Frequency Therapeutics's market cap is calculated by multiplying FREQ's current stock price of $0.36 by FREQ's total outstanding shares of 36,520,750.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.